Autonomix medical, inc. granted new european patent for proprietary catheter-based technology

New patent underscores breadth of application and expansion opportunities for company's catheter-based technology  continued progress with growing global patent portfolio to over 80 issued patents and 40 pending patent applications the woodlands, tx, april 16, 2025 (globe newswire) -- autonomix medical, inc. (nasdaq: amix) (“autonomix” or the “company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that european patent office (epo) has granted patent no. 3,226,792 (the ‘792) titled, “systems and methods for regulating organ and/or tumor growth rates, function, and/or development.
AMIX Ratings Summary
AMIX Quant Ranking